EPZ-5676: Potent DOT1L Inhibitor for MLL-Rearranged Leukemia Research

Executive Summary: EPZ-5676 is a SAM-competitive DOT1L inhibitor with an IC₅₀ of 0.8 nM and >37,000-fold selectivity over other methyltransferases, validated in both biochemical and cellular assays (ApexBio). It induces complete tumor regression in MV4-11 xenograft models at 35–70 mg/kg/day without significant toxicity. EPZ-5676 is insoluble in water but highly soluble in DMSO and ethanol (≥28.15 mg/mL and ≥50.3 mg/mL, respectively). Recommended storage is at -20°C, with DMSO stocks stable for several months. The compound is pivotal for dissecting H3K79 methylation’s role in MLL-rearranged leukemia and for benchmarking histone methyltransferase inhibition assays (Anbazhagan et al. 2024).

Biological Rationale

Epigenetic regulation through histone methylation plays a key role in gene transcription and oncogenesis. DOT1L (disruptor of telomeric silencing 1-like) is the sole methyltransferase for histone H3 lysine 79 (H3K79). Aberrant DOT1L activity leads to sustained H3K79 methylation, upregulation of MLL-fusion target genes, and leukemogenesis, particularly in MLL-rearranged acute leukemias (Anbazhagan et al. 2024). Selective inhibition of DOT1L is a validated strategy to induce cytotoxicity in MLL-translocated leukemia cell lines while sparing normal tissues. This mechanism contrasts with broader histone deacetylase (HDAC) or lysine methyltransferase (KMT) inhibitors, which may lack such selectivity and can disrupt normal chromatin regulation. EPZ-5676 exemplifies a new class of epigenetic tool compounds that enable precise interrogation of H3K79 methylation in both basic and translational research.

Mechanism of Action of DOT1L inhibitor EPZ-5676

EPZ-5676 inhibits DOT1L by competitively occupying the S-adenosyl methionine (SAM) binding pocket. Structural studies show that binding induces a conformational change, creating a hydrophobic pocket beyond the amino acid portion of SAM (ApexBio). This results in potent inhibition of DOT1L’s methyltransferase activity, with an IC₅₀ of 0.8 nM and a K_i value of 80 pM in biochemical assays. The selectivity profile is robust: EPZ-5676 demonstrates >37,000-fold selectivity over other methyltransferases, including CARM1, EHMT1/2, EZH1/2, PRMT family, SETD7, SMYD2/3, and WHSC1/1L1. In cell-based systems, EPZ-5676 reduces H3K79 methylation and suppresses MLL-fusion target gene expression, leading to apoptosis and growth arrest in MLL-rearranged leukemia cells.

Evidence & Benchmarks

• EPZ-5676 inhibits recombinant DOT1L with an IC₅₀ of 0.8 nM under standard assay conditions (50 mM Tris, pH 8.0, 25°C, 1 h) (ApexBio).
• K_i value against DOT1L is 80 pM, confirming sub-nanomolar potency (ApexBio).
• >37,000-fold selectivity over CARM1, EHMT1/2, EZH1/2, PRMTs, SETD7, SMYD2/3, and WHSC1/1L1 assessed in parallel radiometric and AlphaLISA methyltransferase assays (ApexBio).
• EPZ-5676 treatment of MV4-11 leukemia cells results in an IC₅₀ of 3.5 nM for proliferation inhibition after 4–7 days (Anbazhagan et al. 2024).
• In nude rat xenograft models, intravenous administration at 35–70 mg/kg/day for 21 days leads to complete tumor regression without significant toxicity or weight loss (ApexBio).
• DOT1L inhibitor EPZ-5676’s specificity enables targeted dissection of H3K79 methylation, setting it apart from pan-methyltransferase inhibitors (internal article).

Applications, Limits & Misconceptions

EPZ-5676 is primarily used in biochemical DOT1L inhibition assays, cell-based proliferation studies, and in vivo leukemia models. Its antiproliferative effects are most pronounced in MLL-rearranged leukemia cell lines such as MV4-11. The compound is suitable for high-throughput and mechanistic studies of epigenetic regulation in cancer. Due to its selectivity, off-target effects on other methyltransferases are minimal in validated systems. However, EPZ-5676 does not inhibit histone deacetylases (HDACs) or unrelated epigenetic enzymes, nor is it active in solid tumor models lacking DOT1L or MLL rearrangements.

Common Pitfalls or Misconceptions

• EPZ-5676 is not effective against cancers lacking MLL rearrangements or with low DOT1L expression.
• It does not inhibit HDAC or non-DOT1L methyltransferase targets at relevant concentrations.
• EPZ-5676 is insoluble in water; improper solvent selection can compromise assay fidelity.
• Prolonged storage of EPZ-5676 solutions, especially above -20°C, leads to decreased potency.
• In vitro selectivity does not guarantee equivalent selectivity in all in vivo tissues; tissue-specific metabolism may affect exposure.

This article expands on "EPZ5676: Potent DOT1L Inhibitor Advancing Leukemia Research" by providing updated quantitative benchmarks and clarifying the compound's specificity limits. For deeper mechanistic analysis, see "DOT1L Inhibitor EPZ-5676: Advancing Epigenetic Immune Mod...", which discusses the broader immunomodulatory context. This article also complements "EPZ5676: Deep Dive into DOT1L Inhibition and Epigenetic C..." by emphasizing practical workflow integration.

Workflow Integration & Parameters

EPZ-5676 (SKU: A4166) is supplied as a solid with a molecular weight of 562.71. It is soluble at ≥28.15 mg/mL in DMSO and ≥50.3 mg/mL in ethanol using ultrasonic assistance. The compound is insoluble in water. For biochemical assays, stock solutions are typically prepared in DMSO and stored at -20°C. Avoid long-term storage of solutions; stocks remain stable for several months at -20°C. In cell-based assays, EPZ-5676 is used at concentrations ranging from 1–100 nM, with 3.5 nM sufficient for robust inhibition in MV4-11 cells after 4–7 days. For in vivo studies, dosing regimens of 35–70 mg/kg/day (IV, 21 days) are validated. DOT1L inhibitor EPZ-5676 is available for research use at ApexBio.

Conclusion & Outlook

EPZ-5676 sets the standard for potent and selective DOT1L inhibition in MLL-rearranged leukemia research. Its biochemical and in vivo efficacy, coupled with a favorable selectivity profile, enables precise studies of H3K79 methylation and its oncogenic consequences. Future research may explore combination therapies or novel indications, but its primary utility remains in mechanistic and translational leukemia models. For researchers seeking a validated tool for epigenetic regulation in cancer, DOT1L inhibitor EPZ-5676 remains indispensable.